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Abstract
The Gorham-Stout disease is a very rare condition, characterized by lymphovascular proliferation and massive bone resorp-
tion. We present a 48-year-old male patient with osteolysis involving the left femoral head and neck, as well as to the ipsilateral 
acetabulum. Besides the morphological imaging, he underwent bone scintigraphy, technetium-99m-V-dimercaptosuccinic acid 
[99mTc(V)-DMSA] single photon emission computed tomography/computed tomography (SPECT/CT) and histological examina-
tion. Together these findings gave the definitive diagnosis. This is the first case ever published with 99mTc(V)-DMSA SPECT-CT. 
Advances on the knowledge of disease suggests that this imaging procedure could have utility in diagnosis and evaluation of 
the disease activity and therapy response.
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Background
The Gorham-Stout disease is a rare entity of unknown etiology, 
with no inheritance pattern [1, 2], and no gender or racial predi-
lection [3]. It may occur at any age, but is most common among 
adolescents and young adults [1, 3, 4]. It is characterized by 
non-neoplastic proliferation of vascular or lymphovascular tissue, on 
a fibrous connective tissue matrix, associated with progressive bone 
resorption of one or more contiguous bones around one focus, 
which do not respect for joint boundaries [3, 5]. It displays mono-
centric osteolysis, but may exceptionally appear as multicentric 
[1, 6]. Although it may involve any part of the skeleton, the maxilla, 
mandible, clavicle, ribs, cervical vertebrae, pelvis and femur are the 
most common bones involved [4]. The disease has a progressive 
course, but it can reach a quiescent stage, in a spontaneous and 
unpredictable way, after which there is no bone regeneration [1, 
7, 8]. Some Nuclear Medicine imaging procedures, such as bone 
scintigraphy, 99mTc(V)-DMSA scintigraphy and 18F-FDG PET, were 
described as helpful in the diagnosis and assessment of disease 
extension and activity [9–14]. To the authors’ knowledge, so far, 
only one case reporting the use of 99mTc(V)-DMSA scintigraphy 
was published [9].
We present a case of multifocal Gorham-Stout disease involving 
the left femur, extending to the ipsilateral pelvis, evaluated by bone 
scintigraphy, 99mTc(V)-DMSA SPECT-CT, CT, MRI and histological 
examination.
Case report
A 48-year-old male patient presented with a prior history of 
intravenous drug abuse, smoking habits, spontaneously resolved 
hepatitis B and C, cryoglobulinemia, and a car accident in 2006. 
From the accident resulted a thoracic wall hematoma, complicated 
with infection and chronic osteomyelitis of the left 5th and 6th ribs, 
which were resected in the meantime. He had no known relevant 
family history or renal pathology. 
The patient has presented a 4-year history of left hip pain, ac-
companied by progressive functional disability.
Imaging findings
In 2010, as a part of the initial diagnostic approach, the patient 
underwent a radiography, which revealed left coxarthrosis, and 
was then referenced to our department for performing a three-phase 
bone scintigraphy with SPECT of the hips. This revealed decreased 
tracer uptake in the left femoral head and neck, and dysmorphia of 
the hip joint. Subsequently, MRI (Fig. 1) showed an almost complete 
resorption of the left femoral head and neck, extending to the upper 
acetabular anterior column and the iliac wing, with no evidence of 
subcortical sclerosis, periosteal reaction, bone erosion, change 
of the bone marrow signal or joint effusion. The bone was appar-
ently replaced by a soft tissue mass, hypointense at T1-weighted 
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image, with intermediate signal in T2-weighted and proton density 
images, and with mild and heterogeneous contrast uptake. In order 
to better characterize the findings and help to rule out avascular 
necrosis of the femoral head, CT (Fig. 2) was performed which 
was in accordance with the MRI diagnostic findings.
Alkaline phosphatase was elevated in successive tests during 
2011. Since then, it has been normal. In 2013, a hip biopsy was car-
ried out and the histological examination showed fibrous connective 
tissue with variable collagenous density, some areas of dense hya-
line sclerosis and small vessels scattered. Bone was not identified.
The conjunction of the clinical, imaging and histological find-
ings made the diagnosis of Gorham-Stout disease possible.
Follow-up
After the diagnosis, a watchful waiting was adopted. During 
follow-up there was a persistence of complaints.
Bone scan
In 2014, the patient was reevaluated with three-phase bone 
scintigraphy (Fig. 3) which maintained similar findings regarding 
the previous procedure over the left hip, but also revealed a new 
focus of increased tracer uptake in the lower third of the left femoral 
diaphysis.
Figure 1A–C. MRI of hip joints; A. T1-weighted spin-echo; B. T2-weighted turbo spin echo with fat suppression imaging; C. Gadolinium-enhanced 
T1-weighted turbo spin echo with fat suppression. Almost complete resorption of the left femoral head and neck, extending to the upper acetabular 
anterior column and the iliac wing, and replacement by a soft tissue mass
Figure 2. CT scan of hip joints. It confirmed the findings of MRI
Figure 3. Whole body bone scintigraphy (2014) showing dysmorphia 
of left hip joint and mild decrease in tracer uptake involving adjacent 
bones, as well as a focal increased tracer uptake in the lower third of 
the left femur
99mTc(V)-DMSA scintigraphy
In order to evaluate the disease activity, a decision was made 
to perform whole body 99mTc(V)-DMSA scintigraphy (Fig. 4A) with 
SPECT-CT of the hips (Fig. 4B). The images were obtained in 
a dual-head gamma camera (GE Infinia Hawkeye 4®) equipped with 
low-energy high-resolution collimators and a four-slice CT scanner. 
The patient underwent an intravenous injection of 740 MBq 99mTc(V)-
-DMSA and after 2 h 30 min, a whole body scintigraphy was per-
formed (scanning speed 10 cm/min). The SPECT/CT was acquired 
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immediately after planar images (SPECT: step-and-shoot 3°/3°, 
orbit 360°, 25 s/projection, matrix 64 × 64, zoom 1.0; CT: 140 kV, 
2.5 mA). This exam revealed increased tracer uptake in the same 
topography of the low density lesions (as seen in the low-dose CT) 
in the left femoral head and neck and ipsilateral acetabulum, which 
also coincided with the regions of decreased tracer uptake seen 
in the bone scintigraphy. Additionally, increased and heterogene-
ous uptake was evidenced on the lower third of the left femoral 
diaphysis, in the same area of increased 99mTc-HDP uptake. 
The persistence of complaints, the appearance of a new lesion 
in the left femur and an increased 99mTc(V)-DMSA uptake in lytic le-
sions of the hip and distal femur, as well as histological evidence of 
vascular proliferation (instead of only fibrous tissue) in the lesions in 
the left hip, were all in favor of persistent disease activity. A non-in-
vasive therapeutic approach with bisphosphonates was chosen, in 
order to induce remission, and then to attempt total hip arthroplasty.
Discussion
The Gorham-Stout disease is a rare condition, with around 300 
cases published in the literature [4], since its first description by 
Gorham and Stout, 50 years ago [5].
The diagnosis requires a conjunction of clinical, imaging and 
histological findings, as well as the exclusion of any other cause 
of primary or secondary osteolysis [3, 15–17].
Clinical presentation is variable and depends, in part, on the 
body region involved [2]. Some patients may be asymptomatic 
until undergoing a fracture triggered by minor trauma [4, 18], 
whereas others complain of localized pain, edema, progressive de-
formity, contractures, muscle atrophy and functional disability [3, 2]. 
The extension of the disease from the ribs, sternum, scapula or 
vertebrae to the mediastinum, with the invasion of the thoracic duct, 
can lead to pleural or chylous pericardial effusion, and respiratory 
and cardiac failure, respectively [18–22]. Paraplegia may occur in 
cases involving the spine, with vertebral fracture and spinal cord 
compression [23]. The case we report is mainly characterized by 
the involvement of the left hip joint, resulting in prominent pain and 
functional disability of that joint.
In the early stage of the disease, the radiographic features are 
radiolucent foci in the intramedullary and subcortical regions. As the 
disease progresses, these foci enlarge and coalesce, and there 
is cortical and, eventually, adjacent soft tissue involvement. Concentric 
retraction is also noticed, giving it a “sucked candy” appearance. In 
several cases, bone dissolution progresses until a portion or the whole 
bone has been reabsorbed and replaced by fibrous tissue. Fracture, 
fragmentation and soft tissue atrophy may occur. The process can 
also extend to adjacent bones [2, 4, 24]. Usually there is no bone 
sclerosis or periosteal reaction, though it has been described [25].
In two previous reports, magnetic resonance imaging revealed 
a lesion, iso- or hypointense at T1-weighted image and hyperin-
tense at T2-weighted image and a reticular pattern in the contrast 
study [18, 26].
Radiographic features of osteolysis in our case were similar to 
those described in the literature. The absence of marginal sclerosis, 
periosteal reaction or bone regeneration was useful in the differential 
diagnosis with other causes of osteolysis. Magnetic resonance 
findings partially agreed with previous reports. The T1-weighted 
and contrast study presented similar findings, but the T2-weighted 
study showed an intermediate signal instead of the hyperintense 
signal previously reported [18, 26].
Figure 4A. 99mTc(V)-DMSA scintigraphy showing an increased tracer uptake in the left hip joint, and lower third of the left femur. Note: Due to 
claustrophobia, the patient did not conclude the whole body scan and a spot view of the head region was necessary; B. 99mTc(V)-DMSA SPECT-CT 
of hip joints revealing increased tracer uptake involving the left femoral head and neck and ipsilateral acetabulum
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The changes described in literature addressing bone scintigra-
phy are variable. It has been described an increased tracer uptake 
in the vascular and blood pool phases, and a decreased late bone 
uptake, eventually with a high marginal uptake [2, 11, 12], or else 
an increased tracer uptake throughout the lesion, in the bone phase 
[1, 25]. In our case, bone scintigraphy showed a different pattern of 
low tracer uptake in the initial phases, although also a decreased 
tracer uptake in the bone phase, as previously documented. The 
appearance of a second femoral lesion separated from the former 
one by normal bone is very rare and a sign of disease activity [1, 3].
Until now, only one case using 99mTc(V)-DMSA scintigraphy 
was published, showing intense uptake in the multiple osteolytic 
lesions [9]. The 99mTc(V)-DMSA is a nonspecific tumor-seeking 
agent, initially used for the evaluation of medullary thyroid car-
cinoma. Its usefulness has also been reported in the evaluation 
of many other types of cancer, such as head and neck, soft tis-
sue, and breast [27, 28]. Its mechanism of uptake is thought to 
be due to the structural similarity between 99mTc-(V)DMSA core 
(phosphate-like ion TcO4
−3) and phosphate (PO4 
−3) anion [28]. 
It is considered that 99mTc(V)-DMSA enters the cells through the 
type III NaPi co-transporter [27]. Activated platelet-derived growth 
factor receptor (PDGF-R) appears to be involved in this transport 
mechanism [27] and an experimental model showed that PDGF-BB 
is a strong stimulator of the type III NaPi co-transporter [29]. It is wor-
thy to note that expression of the platelet-derived growth factor beta 
receptor (PDGFR-b) and of the platelet-derived growth factor-BB 
(PDGF-BB) was noticed in a case of Gorham’s disease  [30]. 
Since the PDGFR-b is an important lymphangiogenic factor [31], 
this finding suggests this signal pathway may be involved in the 
development of the disease.
It is also interesting that the inhibitor of PDGF-R tyrosine kinase, 
imatinib, suppresses the expression of type III NaPi co-transporter, 
as well as 99mTc(V)-DMSA uptake in vitro [27]. Other studies showed 
a relation between the in vivo 99mTc(V)-DMSA uptake and the 
proliferation rate measured by the expression of Ki-67 and by the 
phosphorylated focal adhesion kinase [27]. It was also described 
an inverse relation between pH and 99mTc(V)-DMSA uptake, where 
glucose-mediated acidosis stimulated 99mTc(V)-DMSA uptake [28].
Several mechanisms were proposed for explaining bone re-
sorption, including the lymphovascular proliferation, the increase 
in number and/or activity of osteoclasts and the decrease of os-
teoblastic activity. Abnormal vascular proliferation may promote 
osteolysis directly by bone compression, indirectly by secretion 
of factors that influence the osteoblastic and/or osteoclastic ac-
tivity, or even more indirectly by reducing blood flow in abnormal 
vessels, leading to hypoxia with subsequent pH decreasing and 
increased hydrolytic enzyme activity [4, 18]. Lymphangiogene-
sis may be promoted by growth factors in a microenvironment of 
activated receptors, on the surface of lymphatic endothelial cells. 
In addition to the PDGF-R pathway, which was already stressed, 
the vascular endothelial growth factor family can also be in-
volved [4]. There are a few reports of increased serum VEGF-C, 
as well as of increased serum and plasma VEGF-A, in patients with 
Gorham-Stout disease [4].
Since 99mTc(V)-DMSA uptake depends on the expression of 
platelet-derived growth factor receptor (including the beta subtype 
— PDGFR-b) and likely of PDGF-BB, and since the expression of 
both seems to be increased in Gorham-Stout disease, this could 
explain an increased 99mTc(V)-DMSA uptake in this pathology. On 
the other hand, because in a late stage of the disease, the fibro-
vascular tissue from the lytic region is replaced by fibrous tissue 
[32], and the 99mTc(V)-DMSA uptake seems to depend on the pres-
ence of lymphovascular tissue, this radiopharmaceutical may be 
of particular value to assess disease activity. On the other hand, 
Ki-67 expression, a cellular proliferation marker, is not increased 
in Gorham-Stout disease and probably do not have an important 
role in 99mTc(V)-DMSA uptake. The 99mTc(V)-DMSA scintigraphy may 
have value in the diagnosis, evaluation of disease extension and 
activity, therapeutic response assessment and research of new 
therapeutic agents efficacy, such as, imatinib [30].
Meanwhile, there is no entirely effective therapy [2, 7]. Surgical 
treatment consists in the resection of the affected bone and, eventu-
ally in the placement of a bone graft or prosthesis. In cases requiring 
arthroplasty, the appropriate resection of the complete extension 
of the lesion ensures a good prognosis without recurrence, even 
in those cases where the disease was still active at the moment 
of intervention [3]. Regarding medical treatment, the benefit of 
external radiotherapy, bisphosphonates and interferon alpha-2b, 
was described [3]. Radiotherapy can be used in combination with 
surgery [33].
In conclusion, we reported a very rare case of Gorham-Stout 
disease, probably multifocal. This is the first case evaluated by 
99mTc(V)-DMSA SPECT-CT. This imaging procedure was important 
to evaluate activity, extension and multifocality of the disease. The 
current knowledge of Gorham-Stout disease and of the 99mTc(V)-
-DMSA uptake mechanism suggests that the augmented uptake 
might result from increasing local expression of PDGFR-b and 
PDGF-BB, as well as from a decreased tissue pH. The demonstra-
tion of this may assign further value to 99mTc(V)-DMSA scintigraphy 
in diagnosing and evaluating disease activity, disease extension, 
and therapeutic response, as well as in evaluating new effective 
therapeutic agents.
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